Reality Check on Neutropenia
Market access for neutropenia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: About 40% of the covered lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions
- Class Trends: The presence of biosimilars may help keep prices down
- Key Findings: The surge of pipeline biosimilars will mean increased competition. Granix and Zarxio utilization is on the rise, which is taking market share from Neulasta and Neupogen
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.